Loading clinical trials...
Loading clinical trials...
A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in Patients With MAPK Pathway-driven Advanced Solid Tumors With a Documented RAS, NF1, or RAF Mutation or Patients Who Have Failed BRAF/MEK Inhibition
Conditions
Interventions
PAS-004 Capsules
PAS-004 Tablets
Locations
7
United States
NEXT Oncology
Austin, Texas, United States
NEXT Oncology
Irving, Texas, United States
NEXT Oncology
San Antonio, Texas, United States
NEXT Oncology
Fairfax, Virginia, United States
MBAL Sveta Sofia
Sofia, Bulgaria
Institute of Oncology Bucharest Prof. Dr. Alexandru Trestioreanu
Bucharest, Romania
Start Date
February 29, 2024
Primary Completion Date
February 1, 2026
Completion Date
February 1, 2027
Last Updated
December 3, 2025
NCT05735717
NCT04395495
NCT06922591
NCT04776655
NCT04973163
NCT06106308
Lead Sponsor
Pasithea Therapeutics Corp.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions